All In Biotech

Drug Trial Radar · NCT05400330

Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease

Long-Term Follow-Up to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Actual

Start

May 8, 2023

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
Lexeo TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study LX100101. A secondary objective is to assess the biomarker as shown by the conversion of CSF APOE isoforms from APOE4 to APOE2-APOE4. Additional secondary outcomes include amyloid PET scan, CSF markers (including Aβ42, Aβ42/Aβ40 ratio T--tau, and P-tau), and quantitative MRI (and other biomarkers that may be informative for this therapeutic approach). Other secondary objectives include instruments to assess cognitive and clinical AD and to evaluate if treatment with AAVrh.10hAPOE2 improves brain tau pathology with tau PET scan (LX1001-01 Cohorts 3 and 4 only).

Conditions

  • Alzheimer Disease

Interventions

  • LX1001Biological

    Gene therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse eventsTime frame: 260 weeks
  2. Incidence of serious adverse eventsTime frame: 260 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • PPD- Orlando Research Unit

    Orlando, Florida

  • Duke University

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.